Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G CHRISTENSEN

Showing results (471-480 of 608) with videos related to

Pageof 61
Sort By:
The Journal of Pathology|April 30, 2009
met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcomaRaffaella De Maria, Silvia Miretti, Selina Iussich, et al.
Cancer Research|September 23, 2003
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinaseMartin Sattler, Yuri B Pride, Patrick Ma, et al.
Cancer Immunology, Immunotherapy : CII|November 11, 2017
The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapyDavid Briere, Niranjan Sudhakar, David M Woods, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 14, 2007
Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PETJeffrey R Tseng, Keon Wook Kang, Mangal Dandekar, et al.
Stem Cells (Dayton, Ohio)|June 11, 2017
Elucidation of Altered Pathways in Tumor-Initiating Cells of Triple-Negative Breast Cancer: A Useful Cell Model System for Drug ScreeningAnne G Christensen, Sidse Ehmsen, Mikkel G Terp, et al.
Cancer Research|October 19, 2010
HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumorsFarbod Shojaei, Joseph H Lee, Brett H Simmons, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitorsPaolo Accornero, Giuseppe Lattanzio, Tony Mangano, et al.
Molecular Cancer Therapeutics|November 1, 2008
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cellsThomas Bachleitner-Hofmann, Mark Y Sun, Chin-Tung Chen, et al.
Integrative Biology : Quantitative Biosciences From Nano to Macro|August 16, 2014
Elucidation of epithelial-mesenchymal transition-related pathways in a triple-negative breast cancer cell line model by multi-omics interactome analysisJosch K Pauling, Anne G Christensen, Richa Batra, et al.
Environmental Science & Technology|February 21, 2008
Characterization and quantification of pneumatic fracturing effects at a clay till siteCamilla Maymann Christiansen, Charlotte Riis, Stine B Christensen, et al.
Pageof 61

Showing results (471-480 of 608) with videos related to

Sort By:
Pageof 61
The Journal of Pathology|April 30, 2009
met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcomaRaffaella De Maria, Silvia Miretti, Selina Iussich, et al.
Cancer Research|September 23, 2003
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinaseMartin Sattler, Yuri B Pride, Patrick Ma, et al.
Cancer Immunology, Immunotherapy : CII|November 11, 2017
The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapyDavid Briere, Niranjan Sudhakar, David M Woods, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 14, 2007
Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PETJeffrey R Tseng, Keon Wook Kang, Mangal Dandekar, et al.
Stem Cells (Dayton, Ohio)|June 11, 2017
Elucidation of Altered Pathways in Tumor-Initiating Cells of Triple-Negative Breast Cancer: A Useful Cell Model System for Drug ScreeningAnne G Christensen, Sidse Ehmsen, Mikkel G Terp, et al.
Cancer Research|October 19, 2010
HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumorsFarbod Shojaei, Joseph H Lee, Brett H Simmons, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitorsPaolo Accornero, Giuseppe Lattanzio, Tony Mangano, et al.
Molecular Cancer Therapeutics|November 1, 2008
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cellsThomas Bachleitner-Hofmann, Mark Y Sun, Chin-Tung Chen, et al.
Integrative Biology : Quantitative Biosciences From Nano to Macro|August 16, 2014
Elucidation of epithelial-mesenchymal transition-related pathways in a triple-negative breast cancer cell line model by multi-omics interactome analysisJosch K Pauling, Anne G Christensen, Richa Batra, et al.
Environmental Science & Technology|February 21, 2008
Characterization and quantification of pneumatic fracturing effects at a clay till siteCamilla Maymann Christiansen, Charlotte Riis, Stine B Christensen, et al.
Pageof 61